US5688785A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5631365A
(en)
*
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
JPH10501811A
(ja)
*
|
1994-06-20 |
1998-02-17 |
シェーリング コーポレイション |
低コレステロール化剤として有用な置換アゼチジノン化合物
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US5624920A
(en)
*
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5633246A
(en)
*
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
CA2231808C
(fr)
*
|
1995-09-27 |
2007-05-22 |
Schering Corporation |
Processus de reduction microbienne stereoselective
|
EP0766962A3
(fr)
*
|
1995-10-03 |
2000-05-10 |
Beiersdorf-Lilly GmbH |
Traitement de l'athérosclérose
|
US5843938A
(en)
*
|
1995-10-03 |
1998-12-01 |
Beiersdorf-Lilly Gmbh |
Treatment of atherosclerosis
|
CN1103780C
(zh)
*
|
1995-10-31 |
2003-03-26 |
先灵公司 |
用作降低血胆固醇药剂的糖取代2-氮杂环丁酮
|
AU7472896A
(en)
*
|
1995-11-02 |
1997-05-22 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
|
WO1997030707A1
(fr)
|
1996-02-23 |
1997-08-28 |
Eli Lilly And Company |
ANTAGONISTES DU RECEPTEUR DE LA VASOPRESSINE V1a NON PEPTIDYLIQUES
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US5739321A
(en)
*
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
US5756470A
(en)
*
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
FR2762336B1
(fr)
*
|
1997-04-21 |
1999-06-11 |
Francois Trantoul |
Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
|
US6133001A
(en)
*
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
US5919672A
(en)
*
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
EP1137634B1
(fr)
*
|
1998-12-07 |
2005-06-15 |
Schering Corporation |
Procede relatif a la synthese d'azetidinones
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
AU2157400A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
|
EP1140188B1
(fr)
*
|
1998-12-23 |
2003-05-28 |
G.D. Searle LLC. |
Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle utilisees dans le cadre de maladies cardio-vasculaires
|
NZ512532A
(en)
*
|
1998-12-23 |
2003-12-19 |
G |
Combinations for treating cardiovascular diseases like hypercholesterolemia and atherosclerosis
|
ES2201822T3
(es)
|
1998-12-23 |
2004-03-16 |
G.D. Searle Llc |
Combinaciones de inhibididores de la proteina de transferencia de ester de colesterilo y de derivados de acido nicotinico para indicaciones cardiovasculares.
|
ATE242008T1
(de)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
EA004231B1
(ru)
*
|
1998-12-23 |
2004-02-26 |
Джи.Ди.Сирл Ллс |
Сочетание ингибиторов белка, переносящего эфир холестерила, и производных фибриновой кислоты для сердечно-сосудистых показаний
|
ATE228012T1
(de)
*
|
1998-12-23 |
2002-12-15 |
Searle Llc |
Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
EP1140189B1
(fr)
*
|
1998-12-23 |
2003-05-14 |
G.D. Searle LLC. |
Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et de derives de l'acide fibrique utilisees dans le cadre de maladies cardio-vasculaires
|
EP2281899A3
(fr)
|
1999-04-05 |
2012-01-04 |
Schering Corporation |
Réduction microbienne stéréosélective pour la préparation de 1-(4-fluorophenyl)-3(R)-3(S)-hydroxy-3-(4-fluorophenyl)propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
US6297268B1
(en)
|
1999-11-30 |
2001-10-02 |
Schering Corporation |
Imidazoles as cholesterol lowering agents
|
WO2001068096A2
(fr)
*
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Polytherapie pour la prophylaxie et le traitement d'etats et de troubles hyperlipidemiques
|
JP2003528830A
(ja)
|
2000-03-10 |
2003-09-30 |
ファルマシア・コーポレーション |
テトラヒドロベンゾチエピン類の製造方法
|
US6584357B1
(en)
*
|
2000-10-17 |
2003-06-24 |
Sony Corporation |
Method and system for forming an acoustic signal from neural timing difference data
|
WO2002036124A2
(fr)
*
|
2000-10-30 |
2002-05-10 |
Schering Corporation |
Procede de traitement
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
EP1510521A1
(fr)
*
|
2000-12-20 |
2005-03-02 |
Schering Corporation |
2-azetidinones substitués par le sucre utilisés comme agents hypocholestérolémiants
|
ES2287826T3
(es)
|
2000-12-20 |
2007-12-16 |
Schering Corp |
2-azetidinonas sustituidas con hidroxi utiles como agentes hipocolesterolemicos.
|
EP1593670B1
(fr)
*
|
2000-12-20 |
2007-08-08 |
Schering Corporation |
2-Azétidinones substitués par hydroxy utilisés comme hypocholestérolémiants
|
DE50111751D1
(de)
*
|
2000-12-21 |
2007-02-08 |
Sanofi Aventis Deutschland |
Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
|
IL156552A0
(en)
*
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
DE60221798T2
(de)
*
|
2001-01-26 |
2008-06-05 |
Schering Corp. |
Kombinationen von gallensäure sequestriermitteln und hemmern der sterol absorption zur behandlung von kardiovaskulären indikationen
|
EP1911462A3
(fr)
|
2001-01-26 |
2011-11-30 |
Schering Corporation |
Combinaisons comprenant un inhibiteur d'absorption de stérol
|
BR0206654A
(pt)
*
|
2001-01-26 |
2004-02-25 |
Schering Corp |
Combinações de ativador(es) de receptor ativado por proliferação de peroxisoma (ppar) e inibidor(es) de absorção de esterol e tratamentos para indicações vasculares
|
PL369033A1
(en)
*
|
2001-01-26 |
2005-04-18 |
Schering Corporation |
Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
|
AU2008201609B8
(en)
*
|
2001-01-26 |
2009-01-08 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
RS50406B
(sr)
*
|
2001-01-26 |
2009-12-31 |
Schering Corporation, |
Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
|
HUP0303917A2
(hu)
*
|
2001-01-26 |
2004-03-01 |
Schering Corporation |
Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
|
AU2005246926B2
(en)
*
|
2001-01-26 |
2008-02-28 |
Merck Sharp & Dohme Corp. |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
US20020183305A1
(en)
*
|
2001-01-26 |
2002-12-05 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
AU2007201970B2
(en)
*
|
2001-01-26 |
2008-04-17 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
AU2006202618B2
(en)
*
|
2001-01-26 |
2007-04-19 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
AU2006203175B2
(en)
*
|
2001-01-26 |
2008-07-24 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
TWI291957B
(en)
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
ATE305459T1
(de)
*
|
2001-03-28 |
2005-10-15 |
Schering Corp |
Verfahren für die enantioselektive synthese von azetidinon-zwischenprodukten
|
AR038956A1
(es)
*
|
2001-05-25 |
2005-02-02 |
Schering Corp |
Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
SI1429756T1
(sl)
*
|
2001-09-21 |
2007-02-28 |
Schering Corp |
Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
DE60216300T2
(de)
*
|
2001-09-21 |
2007-06-28 |
Schering Corp. |
Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
|
BR0213501A
(pt)
*
|
2001-11-02 |
2004-08-24 |
Searle Llc |
Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
|
JP2006506314A
(ja)
*
|
2001-11-09 |
2006-02-23 |
アセロジエニクス・インコーポレイテツド |
心血管疾患の逆転及び予防方法
|
RU2004121898A
(ru)
*
|
2001-12-19 |
2006-01-20 |
Атеродженикс, Инк. (Us) |
Производные халкона и их применение для лечения заболеваний
|
US7202247B2
(en)
|
2001-12-19 |
2007-04-10 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
FR2833842B1
(fr)
*
|
2001-12-21 |
2004-02-13 |
Aventis Pharma Sa |
Compositions pharmaceutiques a base de derives d'azetidine
|
MXPA04006255A
(es)
|
2002-01-17 |
2004-09-27 |
Pharmacia Corp |
Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
|
WO2003074101A1
(fr)
*
|
2002-02-28 |
2003-09-12 |
Eli Lilly And Company |
Procede servant a traiter l'atherosclerose et l'hypercholesterolemie
|
US20040116510A1
(en)
*
|
2002-03-05 |
2004-06-17 |
Nichtberger Steven A. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
DE10227508A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
WO2004004665A2
(fr)
|
2002-07-09 |
2004-01-15 |
Bristol-Myers Squibb Company |
Derives heterocycliques substitues utilises en tant qu'agents contre le diabete et contre l'obesite, et methode associee
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
US6933292B2
(en)
*
|
2002-07-30 |
2005-08-23 |
Children's Medical Center Corporation |
Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
|
US20040181075A1
(en)
*
|
2002-12-19 |
2004-09-16 |
Weingarten M. David |
Process of making chalcone derivatives
|
EP1606287B1
(fr)
*
|
2003-03-07 |
2013-10-02 |
Merck Sharp & Dohme Corp. |
Composés d'azetidinone substitués, formulations et utilisations de ceux-ci pour traiter l'hypercholestérolémie
|
US7235543B2
(en)
|
2003-03-07 |
2007-06-26 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
DE602004018617D1
(de)
*
|
2003-03-07 |
2009-02-05 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
WO2004099132A2
(fr)
*
|
2003-05-05 |
2004-11-18 |
Ranbaxy Laboratories Limited |
Procede pour la preparation de trans-isomeres de derives de diphenylazetidinone
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
RS20050890A
(en)
*
|
2003-05-30 |
2007-12-31 |
Ranbaxy Laboratories Limited, |
Substituted pyrrole derivatives
|
EP1635813A4
(fr)
*
|
2003-06-06 |
2009-07-01 |
Merck & Co Inc |
Polytherapie permettant de traiter la dyslipidemie
|
CA2533392A1
(fr)
*
|
2003-07-24 |
2005-02-03 |
Merck & Co., Inc. |
Cycloalcanes diphenyl-substitutes, compositions contenant ces composes, et procedes d'utilisation
|
AU2003259547A1
(en)
*
|
2003-07-31 |
2005-02-14 |
Hetero Drugs Limited |
Ezetimibe polymorphs
|
EP1522541A1
(fr)
*
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Nouveaux composés hypocholesterolémiques
|
WO2005042692A2
(fr)
*
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
Methode permettant d'inhiber l'expression de genes qui induisent l'influx de cholesterol cellulaire dans les cellules animales et d'inhiber la production de proteines issues de l'expression de ces genes
|
EP1918000A2
(fr)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
|
JP2007510659A
(ja)
*
|
2003-11-05 |
2007-04-26 |
シェーリング コーポレイション |
脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
|
DE602004008100T2
(de)
*
|
2003-11-10 |
2008-04-30 |
Microbia Inc., Cambridge |
4-biarylyl-1-phenylazetidin-2-one
|
WO2005049592A1
(fr)
*
|
2003-11-24 |
2005-06-02 |
Hetero Drugs Limited |
Nouveau procede de preparation d'intermediaire d'ezetimibe
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
SA04250427A
(ar)
*
|
2003-12-23 |
2005-12-03 |
استرازينيكا ايه بي |
مشتقات ثاني فينيل أزيتيدون
|
JP2007516287A
(ja)
*
|
2003-12-23 |
2007-06-21 |
メルク エンド カムパニー インコーポレーテッド |
抗高コレステロール血症化合物
|
CA2553769C
(fr)
*
|
2004-01-16 |
2011-01-04 |
Merck & Co., Inc. |
Npc1l1 (npc3) et procedes pour identifier des ligands de ceux-ci
|
ES2399721T5
(es)
|
2004-03-05 |
2016-05-25 |
Univ Pennsylvania |
Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050244367A1
(en)
*
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
CA2567149A1
(fr)
*
|
2004-05-21 |
2005-12-01 |
Sanofi-Aventis Deutschland Gmbh |
Procede pour produire des derives de 1,4-diphenylazetidinone
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US20060063828A1
(en)
*
|
2004-06-28 |
2006-03-23 |
Weingarten M D |
1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
WO2006026273A2
(fr)
*
|
2004-08-25 |
2006-03-09 |
Merck & Co., Inc. |
Procede pour traiter l'atherosclerose, la dyslipidemie et les etats pathologiques associes
|
US20060046996A1
(en)
|
2004-08-31 |
2006-03-02 |
Kowa Co., Ltd. |
Method for treating hyperlipidemia
|
PE20060594A1
(es)
*
|
2004-09-09 |
2006-08-18 |
Novartis Ag |
Composicion farmaceutica que contiene un agonista de ppar
|
WO2006039334A1
(fr)
*
|
2004-09-29 |
2006-04-13 |
Schering Corporation |
Combinaisons d'azetidinones substituees et d'antagonistes cb1
|
US7700597B2
(en)
|
2004-12-03 |
2010-04-20 |
Schering Corporation |
Substituted piperazines as CB1 antagonists
|
JP2008523807A
(ja)
*
|
2004-12-15 |
2008-07-10 |
シェーリング コーポレイション |
コレステロール吸収インヒビターについての機能アッセイ
|
US20130082232A1
(en)
|
2011-09-30 |
2013-04-04 |
Unity Semiconductor Corporation |
Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
|
WO2006107936A1
(fr)
*
|
2005-04-04 |
2006-10-12 |
Pontificia Universidad Catolica De Chile |
Utilisation d'ezetimibe pour prevenir et traiter des calculs biliaires de cholesterol
|
TW200726746A
(en)
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
KR20080023296A
(ko)
*
|
2005-05-09 |
2008-03-13 |
마이크로비아 인코포레이티드 |
유기금속 벤젠포스포네이트 커플링제
|
MX2007014172A
(es)
*
|
2005-05-11 |
2008-04-02 |
Microbia Inc |
Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
US20090099355A1
(en)
*
|
2005-05-25 |
2009-04-16 |
Microbia, Inc. |
Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids
|
EP1893222A4
(fr)
*
|
2005-06-15 |
2010-07-07 |
Merck Sharp & Dohme |
Composes anti-hypercholesterolemiques
|
AU2006262441A1
(en)
*
|
2005-06-20 |
2007-01-04 |
Schering Corporation |
Piperidine derivatives useful as histamine H3 antagonists
|
AR054482A1
(es)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
US8013150B2
(en)
*
|
2005-06-22 |
2011-09-06 |
Msn Laboratories Ltd. |
Process for the preparation of ezetimibe
|
SA06270191B1
(ar)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
EP1741427A1
(fr)
*
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Composition pharmaceutique comprenant la simvastatin et l'ezetimibe
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
WO2007030721A2
(fr)
*
|
2005-09-08 |
2007-03-15 |
Teva Pharmaceutical Industries Ltd. |
Procedes pour preparer (3r,4s)-4-((4-benzyloxy)phenyle)-1-(4-fluorophenyle)-3-((s)-3-(4-fluorophenyle)-3-hydroxypropyle)-2-azetidinone, un intermediaire pour la synthese de l'ezetimibe
|
TW200806623A
(en)
*
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
AU2006304836A1
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
JP2009514851A
(ja)
*
|
2005-11-08 |
2009-04-09 |
ランバクシー ラボラトリーズ リミテッド |
(3r,5r)−7−[2−(4−フルオロフェニル)−5−イソプロピル−3−フェニル−4−[(4−ヒドロキシメチルフェニルアミノ)カルボニル]−ピロール−1−イル]−3,5−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
|
HU0501164D0
(en)
*
|
2005-12-20 |
2006-02-28 |
Richter Gedeon Vegyeszet |
New industrial process for the production of ezetimibe
|
MX2008008340A
(es)
*
|
2005-12-21 |
2008-09-03 |
Schering Corp |
Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
|
CA2634648A1
(fr)
*
|
2005-12-22 |
2007-10-25 |
Medichem, S.A. |
Procedes de preparation de composes intermediaires utilises dans la preparation de l'ezetimibe
|
EP1973877A2
(fr)
|
2006-01-18 |
2008-10-01 |
Schering Corporation |
Modulateurs de recepteurs de cannibinoides
|
KR101074968B1
(ko)
*
|
2006-02-16 |
2011-10-18 |
고토부키 세이야쿠 가부시키가이샤 |
광학활성 알코올을 제조하는 방법
|
WO2007100807A2
(fr)
|
2006-02-24 |
2007-09-07 |
Schering Corporation |
Orthologues de npc1l1
|
JP2009529055A
(ja)
*
|
2006-03-06 |
2009-08-13 |
テバ ファーマシューティカル インダストリーズ リミティド |
エゼチミベ組成物
|
TW200744583A
(en)
*
|
2006-03-14 |
2007-12-16 |
Ranbaxy Lab Ltd |
Statin stabilizing dosage formulations
|
WO2007120824A2
(fr)
*
|
2006-04-10 |
2007-10-25 |
Teva Pharmaceutical Industries Ltd. |
Procédés de synthèse de l'azétidinone
|
TW200811098A
(en)
*
|
2006-04-27 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
AU2007274724B2
(en)
*
|
2006-07-14 |
2012-07-26 |
Ranbaxy Laboratories Limited |
Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
|
JP2009503119A
(ja)
*
|
2006-08-29 |
2009-01-29 |
テバ ファーマシューティカル インダストリーズ リミティド |
(3r,4s)−4−(4−ヒドロキシ保護−フェニル)−1−(4−フルオロフェニル)−3−[3−(4−フルオロフェニル)−3−オキソプロピル]アゼチジン−2−オンを精製する方法
|
MX2009002398A
(es)
*
|
2006-09-05 |
2009-03-16 |
Schering Corp |
Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica.
|
WO2008033468A2
(fr)
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Azétidine et dérivés de l'azétidine utiles dans le traitement de la douleur et des troubles du métabolisme lipidique
|
JP2010503675A
(ja)
*
|
2006-09-15 |
2010-02-04 |
シェーリング コーポレイション |
疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体
|
JP2010503677A
(ja)
*
|
2006-09-15 |
2010-02-04 |
シェーリング コーポレイション |
脂質代謝の障害を治療するためのアゼチジノン誘導体
|
WO2008033465A1
(fr)
*
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Dérivés d'azétidinone et procédés d'utilisation de ceux-ci
|
CN101528746A
(zh)
*
|
2006-09-15 |
2009-09-09 |
先灵公司 |
治疗脂质代谢障碍、疼痛、糖尿病和其它障碍的螺环氮杂环丁酮衍生物
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
CN100564357C
(zh)
*
|
2006-10-20 |
2009-12-02 |
浙江天宇药业有限公司 |
一种氮杂环丁酮衍生物及其合成方法
|
WO2008085300A1
(fr)
*
|
2006-12-20 |
2008-07-17 |
Merck & Co., Inc. |
Composé anti-hypercholestérolémique
|
EP1939174A1
(fr)
*
|
2006-12-21 |
2008-07-02 |
LEK Pharmaceuticals D.D. |
Complexe d'inclusion d'ezetimibe et une cyclodextrine et procédés pour son préparation
|
AU2007338625A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Aegerion Pharmaceuticals, Inc. |
Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
|
CN102285906B
(zh)
*
|
2007-01-24 |
2014-11-19 |
克尔克公司 |
依泽替米贝的制备方法和其的衍生物
|
WO2008096372A2
(fr)
*
|
2007-02-06 |
2008-08-14 |
Ind-Swift Laboratories Limited |
Procédé de préparation de l'ézétimibe extrêmement pur au moyen de nouveaux intermédiaires
|
WO2008104875A1
(fr)
*
|
2007-03-01 |
2008-09-04 |
Pfizer Products Inc. |
Oxazolidinones comme inhibiteurs d'absorption de cholestérol
|
US20100125059A1
(en)
|
2007-03-06 |
2010-05-20 |
Teijin Pharma Limited |
1-biarylazetidinone derivative
|
CL2008000684A1
(es)
|
2007-03-09 |
2008-08-01 |
Indigene Pharmaceuticals Inc |
Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
|
WO2008123953A1
(fr)
*
|
2007-04-02 |
2008-10-16 |
Merck & Co., Inc. |
Composé anti-hypercholestérolémique
|
WO2008130616A2
(fr)
*
|
2007-04-19 |
2008-10-30 |
Schering Corporation |
Diaryl morpholines comme modulateurs des récepteurs cb1
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
JP2010529148A
(ja)
*
|
2007-06-07 |
2010-08-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
エゼチミブ製造のための還元方法
|
US20080318920A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Protia, Llc |
Deuterium-enriched ezetimibe
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
JP2010531361A
(ja)
*
|
2007-06-28 |
2010-09-24 |
インターベット インターナショナル ベー. フェー. |
Cb1アタゴニストとしての置換ピペラジン
|
WO2009005671A2
(fr)
*
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Pipérazines à substitution servant d'antagonistes des récepteurs cb1
|
WO2009016358A2
(fr)
*
|
2007-07-27 |
2009-02-05 |
Cipla Limited |
Compositions pharmaceutiques et leur procédé de préparation
|
WO2009024889A2
(fr)
|
2007-08-21 |
2009-02-26 |
Ranbaxy Laboratories Limited |
Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
|
US20090093627A1
(en)
*
|
2007-08-30 |
2009-04-09 |
Lorand Szabo |
Process for preparing intermediates of ezetimibe by microbial reduction
|
WO2009027785A2
(fr)
*
|
2007-08-30 |
2009-03-05 |
Pfizer Products Inc. |
Composés pharmaceutiques et dérivés
|
DE102007063671A1
(de)
*
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
EP2217214B1
(fr)
|
2007-12-10 |
2017-07-19 |
ratiopharm GmbH |
Formulation pharmaceutique comprenant de l'ézétimibe
|
CZ305066B6
(cs)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
|
EP2128133A1
(fr)
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Procédé et composition d'ézétimibe
|
CA2724873A1
(fr)
*
|
2008-06-06 |
2009-12-10 |
Nicox S.A. |
Compositions comprenant de l'ester 4-(nitrooxy)butylique d'atorvastatine et un medicament hypolipidemique
|
US20090312302A1
(en)
*
|
2008-06-17 |
2009-12-17 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
|
US8273554B2
(en)
|
2008-08-29 |
2012-09-25 |
Codexis, Inc. |
Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
|
KR20110098909A
(ko)
|
2008-11-14 |
2011-09-02 |
보미 피. 팜로즈 |
동맥경화증의 치료를 위한, 순환하는 산화된 저밀도 지방단백질-베타-2-당단백질 1 복합체를 낮추는 방법
|
EP2204170A1
(fr)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Composition pharmaceutique comprenant ézétimide et simvastatine
|
WO2010075069A1
(fr)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques
|
WO2010075068A1
(fr)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Dérivés de pyridopyrimidine et leurs procédés d'utilisation
|
EP2216016A1
(fr)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
|
CA2754384A1
(fr)
|
2009-03-06 |
2010-09-10 |
Lipideon Biotechnology Ag |
Compositions pharmaceutiques hypocholesterolemiques
|
EP2229938B9
(fr)
|
2009-03-13 |
2012-04-25 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Compositions d'ézétimibe
|
WO2010113182A1
(fr)
|
2009-03-31 |
2010-10-07 |
Lupin Limited |
Intermediaires utilises dans la preparation de 1,4-diphenylazetidinone
|
WO2010113175A2
(fr)
|
2009-04-01 |
2010-10-07 |
Matrix Laboratories Ltd |
Procédé enzymatique pour la préparation de la (s)-5-(4-fluorophényl)-5-hydroxy-1-morpholin-4-yl-pentan-1-one, un intermédiaire de l'ézétimibe et la conversion ultérieure en ézétimibe
|
WO2011019326A2
(fr)
|
2009-07-02 |
2011-02-17 |
Mahmut Bilgic |
Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
|
EP2448564A2
(fr)
|
2009-07-02 |
2012-05-09 |
Bilgic Mahmut |
Formulation pharmaceutique améliorant la solubilité
|
WO2011002424A2
(fr)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Préparation pharmaceutique améliorant la solubilité et la stabilité
|
CN101993403B
(zh)
|
2009-08-11 |
2012-07-11 |
浙江海正药业股份有限公司 |
氮杂环丁酮类化合物及医药应用
|
SG178456A1
(en)
|
2009-08-19 |
2012-04-27 |
Codexis Inc |
Ketoreductase polypeptides for the preparation of phenylephrine
|
AU2011220742B2
(en)
|
2010-02-24 |
2016-02-25 |
Relypsa, Inc. |
Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants
|
US9655920B2
(en)
|
2010-02-24 |
2017-05-23 |
Relypsa, Inc. |
Amine polymers for use as bile acid sequestrants
|
EP2538947B1
(fr)
|
2010-02-24 |
2016-08-17 |
Relypsa, Inc. |
Polyimidazoles pour emploi en tant qu'agents séquestrants d'acide biliaire
|
EP2368543A1
(fr)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Procédé de préparation de composition pharmaceutique granulée comprenant de la simvastatine et/ou ézétimibe
|
PL2561069T3
(pl)
|
2010-04-23 |
2017-08-31 |
Alexion Pharmaceuticals, Inc. |
Enzym lizosomalnej choroby spichrzeniowej
|
US9040262B2
(en)
|
2010-05-04 |
2015-05-26 |
Codexis, Inc. |
Biocatalysts for ezetimibe synthesis
|
ES2372460B1
(es)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
CN105457018A
(zh)
|
2010-09-09 |
2016-04-06 |
辛那杰瓦生物制药股份有限公司 |
使用溶酶体酸性脂肪酶来治疗患者的溶酶体酸性脂肪酶缺乏
|
MY180164A
(en)
|
2010-11-08 |
2020-11-24 |
Albireo Ab |
A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
|
BR112013010157B1
(pt)
|
2010-11-08 |
2020-02-04 |
Albireo Ab |
iinibidores do ibat, seus usos, e composição e combinações farmacêuticas
|
WO2012076030A1
(fr)
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Procédé de préparation de composés intermédiaires utiles dans la préparation de l'ézétimibe
|
EP2675472A4
(fr)
|
2011-02-15 |
2014-09-17 |
Synageva Biopharma Corp |
Procédés de traitement d'un déficit en lipase acide lysosomale
|
US8455474B2
(en)
|
2011-03-04 |
2013-06-04 |
Mackay Memorial Hospital |
Method for treating tuberculosis
|
WO2012155932A1
(fr)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Procédé amélioré pour la préparation d'ézétimibe
|
PL231215B1
(pl)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
|
CN102675177A
(zh)
*
|
2011-06-28 |
2012-09-19 |
常州制药厂有限公司 |
一种降血脂药物及其关键中间体的制备方法
|
CN102952055A
(zh)
*
|
2011-08-16 |
2013-03-06 |
凯瑞斯德生化(苏州)有限公司 |
一种依泽替米贝和其中间体的制备方法
|
CN103204795B
(zh)
*
|
2012-01-11 |
2016-12-14 |
重庆华邦胜凯制药有限公司 |
一种手性氮杂环丁酮类化合物的制备方法
|
WO2013166117A1
(fr)
|
2012-05-01 |
2013-11-07 |
Althera Life Sciences, Llc |
Formulation de comprimé oral constituée d'une combinaison fixe de rosuvastatine et d'ézétimibe pour le traitement de l'hyperlipidémie et de maladies cardiovasculaires
|
CN103570574B
(zh)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
一种依泽替米贝的合成方法及该方法中所用的中间体
|
CN103102297A
(zh)
*
|
2012-09-28 |
2013-05-15 |
北京赛林泰医药技术有限公司 |
一种新的依折麦布的合成方法
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
CN103864708A
(zh)
*
|
2012-12-12 |
2014-06-18 |
天津市医药集团技术发展有限公司 |
一种依折麦布中间体的制备方法
|
WO2015039675A1
(fr)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Nouveau procédé de préparation d'intermédiaires d'ézétimibe
|
US9649294B2
(en)
|
2013-11-04 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
US9926269B2
(en)
|
2013-12-18 |
2018-03-27 |
Rudjer Boskovic Institute |
Beta-lactam cholesterol absorption inhibitors
|
CN103739537B
(zh)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
依折麦布的新合成方法
|
KR20150079373A
(ko)
|
2013-12-30 |
2015-07-08 |
한미약품 주식회사 |
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
|
CN103755616A
(zh)
*
|
2013-12-31 |
2014-04-30 |
北京万全德众医药生物技术有限公司 |
一种制备依泽替米贝异构体的方法
|
MX2016015467A
(es)
|
2014-05-30 |
2017-03-23 |
Pfizer |
Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
|
CN105294426B
(zh)
|
2014-06-09 |
2019-05-14 |
浙江海正药业股份有限公司 |
氮杂环丁酮化合物制备方法及其中间体
|
CN104447474A
(zh)
*
|
2014-11-11 |
2015-03-25 |
武汉武药科技有限公司 |
一种依折麦布异构体的合成方法
|
CN104387308A
(zh)
*
|
2014-11-18 |
2015-03-04 |
武汉福星生物药业有限公司 |
一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
|
CN104513187B
(zh)
*
|
2015-01-09 |
2017-05-31 |
安润医药科技(苏州)有限公司 |
依折麦布及其中间体的合成方法
|
JP2016145173A
(ja)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
(3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐(4‐ヒドロキシフェニル)‐2‐アゼチジノンの製造方法
|
UA123355C2
(uk)
|
2015-03-13 |
2021-03-24 |
Есперіон Терапеутікс, Інк. |
Фіксовані комбінації й склади, які містять etc-1002 й езетиміб, і способи лікування або зменшення ризику розвитку серцево-судинного захворювання
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
CN105287513A
(zh)
*
|
2015-10-23 |
2016-02-03 |
浙江永宁药业股份有限公司 |
一种依折麦布药物组合物及其制备方法
|
CN107098841A
(zh)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
一种依折麦布的制备方法及该方法中所用的中间体
|
WO2018103642A1
(fr)
|
2016-12-05 |
2018-06-14 |
Patsnap |
Systèmes, appareils et procédés de recherche et d'affichage d'informations disponibles dans de grandes bases de données selon la similarité de structures chimiques discutées dans celles-ci
|
US20180338922A1
(en)
|
2017-05-26 |
2018-11-29 |
Esperion Therapeutics, Inc. |
Fixed dose formulations
|
EP3437636A1
(fr)
|
2017-08-02 |
2019-02-06 |
Adamed sp. z o.o. |
Composition pharmaceutique comprenant de l'ézétimibe
|
CA3087281A1
(fr)
|
2018-01-16 |
2019-07-25 |
Q.E.D. Environmental Systems, Inc. |
Systeme de surveillance de niveau de fluide et procede incorporant un systeme de capteur de pression ayant un sac gonflable/repliable
|
US11504390B2
(en)
|
2019-03-20 |
2022-11-22 |
Regeneron Pharmaceuticals, Inc. |
Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors
|
EP3942047A1
(fr)
|
2019-03-20 |
2022-01-26 |
Regeneron Pharmaceuticals, Inc. |
Traitement de niveaux de lipides accrus avec des inhibiteurs de protéine d'activation de clivage de protéine de liaison d'élément régulateur de stérol (scap)
|
WO2021019499A1
(fr)
|
2019-07-31 |
2021-02-04 |
TECNIMEDE - Sociedade Técnico-medicinal, SA |
Compositions solides orales à libération immédiate à unités multiples, procédés et utilisations de celles-ci
|
WO2022023206A1
(fr)
|
2020-07-27 |
2022-02-03 |
Krka, D.D., Novo Mesto |
Comprimé bicouche comprenant de l'ézétimibe et de l'atorvastatine
|
KR20240010494A
(ko)
*
|
2021-06-17 |
2024-01-23 |
쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 |
하이뷰티마이브 중간체 및 이의 제조 방법
|
WO2023275715A1
(fr)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Métabolites de modulateurs sélectifs du récepteur des androgènes
|